The cancer genetics testing provider acquired its new business unit from GE Healthcare.
By buying Clarient, NeoGenomics hopes to move closer to its goal of becoming America's top cancer genetic testing lab.
NeoGenomics and GE Healthcare will also collaborate on a bioinformatics initiative for personalized oncology.
The deal gives Axiogenesis access to IP that will allow it to commercialize stem cell-derived assays and disease models for use in drug discovery.
The licenses provide non-exclusive access to the IP for research applications.
General Electric has been awarded
Originally published Oct. 3.
NEW YORK (GenomeWeb) – GE Healthcare today announced a deal between its affiliate Clarient Diagnostic Services and GlaxoSmithKline to create a network of clinical laboratories to identify genetic mutations associated with different tumor types.
Title: Treatment of Cancer by Inhibition of IGFBPs and Clusterin
Patent Number: 8,835,401
Filed: May 29, 2013
GE Healthcare this week launched the illustra Single Cell GenomiPhi DNA amplification kit from.
Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.
In Nature this week: genetic history of HIV in the US, and more.
There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.
A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.